CTIS2023-508259-38-00进行中（未招募）1 期
An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL) - MO40599/GLA 2017-R2
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- GWT-Tud GmbH
- 入组人数
- 334
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •The informed consent form must be signed before any study specific tests or procedures are done, Adequate hematological function, as defined by: hemoglobin = 8 g/dL, if anemia is attributable to underlying disease and transfusions result to an increase = 8 g/dL, patients can be included, absolute neutrophil count (ANC) = 1.0 x 109/L OR = 0.5 x 109/L if neutropenia is attributable to underlying disease and before the administration of steroids, and platelet count = 75 x 109/L OR = 50 x 109/L if thrombocytopenia is attributable to underlying disease, Women of childbearing potential must have a negative pregnancy test result within 7 days prior to the first study drug administration, For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating eggs, For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, Adult male and female patients =18 years (=16 years in the UK*) at the time of inclusion in the study * In the UK an adult” means a person who has attained the age of 16 years, according to The Medicines for Human Use (Clinical Trials) Regulations 2004, Part 1 Point 2, Ability to understand and follow study-related instructions, Risk group: All patients with one of the following histologically defined entities: Histological diagnosis of primary refractory or relapsed aggressive B-cell non-Hodgkin lymphoma (B-NHL), confirmed by a biopsy of involved nodal or extranodal site. Patients with any of the following histologies can be included: • DLBCL not otherwise specified (NOS) • T-cell/histiocyte-rich large B-cell lymphoma • Primary cutaneous DLBCL, leg type • Epstein-Barr virus (EBV)-positive DLBCL, NOS • DLBCL associated with chronic inflammation • Primary mediastinal (thymic) large B-cell lymphoma • High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements • High-grade B-cell lymphoma, NOS, Performance Status ECOG 0-2 at time of randomization or ECOG 3 at screening if this is DLBCL-related and has improved to ECOG 2 or less with a 7-day steroid treatment during the screening phase (e.g. 1 mg/kg prednisone), Information on all 5 International Prognostic Index (IPI) factors, Staging (PET-CT based-staging according to Lugano criteria 2014). Patients must have PET-positive lesions, Subjects must have received adequate first line therapy including at a minimum: i) anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20 negative, and ii) an anthracycline containing chemotherapy regimen, Intent to proceed to high-dose therapy (HDT) and stem cell transplantation (SCT) if response to second line therapy
排除标准
- •Serious accompanying disorder leading to impaired organ function causing significant clinical problems and reduced life expectancy of less than 3 months. In particular, patients with the following organ dysfunction caused by accompanying disorders are to be excluded: • Heart failure with left ventricular ejection fraction (LVEF) < 45% • Impaired pulmonary function with vital capacity (VC) or forced expiratory volume (FEV1) < 50% of normal (only in case of history of significant pulmonary disease) • Impaired renal function with glomerular filtration rate (GFR) < 50 mL/min (calculated) • Impaired liver function with alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT) or bilirubin > 1.5 x upper limit of normal (ULN). If elevation is caused by the disease, threshold of 2.5 x ULN is accepted • Peripheral neuropathy > Grade II, Patients with suspected or latent tuberculosis. Latent tuberculosis needs to be confirmed by positive interferon-gamma release assay, Primary or secondary central nervous system (CNS) lymphoma at the time of recruitment, Richter’s transformation or prior chronic lymphocytic leukemia (CLL), Vaccination with a live vaccine within 4 weeks prior to treatment, Recent major surgery (within 6 weeks before the start of Cycle 1 Day 1) other than for diagnosis, History of severe allergic or anaphylactic reactions to human, humanized, chimeric, or murine monoclonal antibodies, History of hypersensitivity to any of the study drugs or their ingredients or to drugs with similar structure, Contraindications according to the Investigator´s Brochure (IB) of polatuzumab vedotin or the local Summary of Product Characteristics (SmPCs) of the used rituximab, ifosfamide, carboplatin or etoposide products, Criteria which in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the subject’s safety, Pregnancy or breastfeeding, or intending to become pregnant during the study or within 12 months after the last dose of study drug, Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 2 weeks prior to Cycle 1 Day 1, Close affiliation with the investigator (e.g. a close relative) or persons working at the study site, Subject is an employee of the sponsor or involved Contract Research Organization, Received more than one line of therapy for DLBCL, Received polatuzumab vedotin as part of the first line therapy, Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications, Ongoing treatment or study procedures within any other Investigational Medicinal Product (IMP) clinical trial with the exception of follow-up. In case of a preceding clinical trial, last application of the respective IMP(s) must have been done more than five elimination half-lives before start of study medication in this trial, Human immunodeficiency virus (HIV)-positivity with detectable viral load and/or a CD4+ count below 0.3/nL, Hepatitis B and C are defined by seropositivity (HBsAg and anti HBc; anti-HCV). Patients with occult or prior HBV infection (defined as negative HBsAg and positive hepatitis B core antibody [Anti-HBc])
研究者
相似试验
进行中（未招募）
1 期
An unblinded study to compare the treatment success and tolerability of a chemotherapy consisting of a combination of rituximab, ifosfamide, carboplatin and etoposide with and without the addition of polatuzumab vedotin in subject suffering from an aggressive lymphoma, a malignant disease of the lymphatic system.primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)MedDRA version: 20.0Level: LLTClassification code 10003901Term: B-cell lymphoma NOSSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10012820Term: Diffuse large B-cell lymphoma NOSSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10023769Term: Large cell immunoblastic lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractorySystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10012857Term: Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractorySystem Organ Class: 100000004864EUCTR2019-002962-10-ATGWT-TUD GmbH334
进行中（未招募）
3 期
A trial looking at the effectiveness of combining standard R-ICE chemotherapy with another medicine (polatuzumab vedotin) for patients with diffuse large B cell lymphoma that has either, not responded to or returned, following the first treatment receivedRelapsed or refractory diffuse large B-cell lymphomaDiffuse large B-cell lymphomaCancerISRCTN13438605Gesellschaft fur Wissens und Technologietransfer334
已完成
3 期
The effect of haemostatic factor,Octafibrin in congenital afibrinogenemiaIRCT2014112320051N3Octapharma3
招募中
1 期
This study is to understand how well an investigational drug (called Napabucasin) works when given in combination with a chemotherapy treatment for people with colorectal cancer after all available standard treatments.Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic.MedDRA version: 27.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000613-32-FR1Globe Health Institute668
招募中
3 期
MK-3475A SC vs pembrolizumab IV, administered with chemotherapy, in treatment-naive metastatic NSCLCMetastatic Non-small Cell Lung CancerJPRN-jRCT2031230049Koh Yasuhiro39